EP Patent

EP4509178A2 — High purity oritavancin and method of producing same

Assigned to Melinta Therapeutics LLC · Expires 2025-02-19 · 1y expired

What this patent protects

Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.

USPTO Abstract

Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.

Drugs covered by this patent

oritavancin-diphosphate (ORITAVANCIN DIPHOSPHATE)

Patent Metadata

Patent number: EP4509178A2
Jurisdiction: EP
Classification: —
Expires: 2025-02-19
Drug substance claim: No
Drug product claim: No
Assignee: Melinta Therapeutics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.